Inhibikase Therapeutics, Inc. (IKT) Stock Overview
Explore Inhibikase Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Inhibikase Therapeutics, Inc. (IKT)
Key Financials
Key Financials
Market Cap
294.4M
P/E Ratio
-4.12
EPS (TTM)
$-0.43
ROE
-0.41%
IKT Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Inhibikase Therapeutics, Inc. (IKT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 71.75, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $1.53.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.12 and a market capitalization of 294.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.